Original Source(s)
WHtR May Aid OSA Risk Screening
-
by Andrea Surnit
June 4, 2026
Related Content
GLP-1 Drugs Linked to GI Effects, Uncertain Signals
Umbrella review evaluates over 1,700 trials to assess noncardiometabolic outcomes beyond weight and glycemic effects.
April 16, 2026
-
3 min
Retatrutide Shows 28% Weight Loss in Phase 3 Trial
Nearly half of participants receiving the highest dose achieved at least 30% body weight reduction.
May 21, 2026
-
2 min